- Home
- SILC vs GNLX Comparison
SILC vs GNLX Comparison
Compare SILC & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SILC | GNLX |
|---|---|---|
| Founded | 1987 | 2001 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.7M | 113.6M |
| IPO Year | 2002 | 2022 |
Fundamental Metrics
Financial Performance| Metric | SILC | GNLX |
|---|---|---|
| Price | $21.50 | $2.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $19.80 |
| AVG Volume (30 Days) | 45.8K | ★ 155.5K |
| Earning Date | 04-27-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | $17.17 | N/A |
| Revenue Next Year | $12.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.44 | $1.99 |
| 52 Week High | $23.10 | $8.54 |
Technical Indicators
Market Signals| Indicator | SILC | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 57.04 | 41.73 |
| Support Level | $17.75 | $2.33 |
| Resistance Level | $20.96 | $3.00 |
| Average True Range (ATR) | 1.24 | 0.15 |
| MACD | 0.19 | -0.00 |
| Stochastic Oscillator | 58.14 | 23.17 |
Price Performance
Historical ComparisonAbout SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.